Marshall Wace’s Athenahealth, Inc. ATHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-182,403
| Closed | -$24.1M | – | 2259 |
|
|
2018
Q4 | $24.1M | Buy |
182,403
+116,061
| +175% | +$14.9M | 0.25% | 82 |
|
|
2018
Q3 | $8.86M | Buy |
66,342
+40,863
| +160% | +$6.12M | 0.08% | 321 |
|
|
2018
Q2 | $4.05M | Buy |
+25,479
| New | +$3.78M | 0.06% | 334 |
|
|
2017
Q4 | – | Sell |
-5,569
| Closed | -$691K | – | 517 |
|
|
2017
Q3 | $691K | Buy |
5,569
+1,967
| +55% | +$271K | 0.03% | 255 |
|
|
2017
Q2 | $508K | Buy |
+3,602
| New | +$450K | 0.02% | 239 |
|
|
2016
Q3 | – | Sell |
-2,202
| Closed | -$304K | – | 1234 |
|
|
2016
Q2 | $304K | Sell |
2,202
-91,590
| -98% | -$12.1M | ﹤0.01% | 897 |
|
|
2016
Q1 | $13M | Buy |
93,792
+56,593
| +152% | +$7.76M | 0.13% | 168 |
|
|
2015
Q4 | $5.99M | Buy |
37,199
+24,284
| +188% | +$3.75M | 0.06% | 340 |
|
|
2015
Q3 | $1.72M | Buy |
+12,915
| New | +$1.68M | 0.02% | 488 |
|
|
2014
Q3 | – | Sell |
-2,400
| Closed | -$300K | – | 1126 |
|
|
2014
Q2 | $300K | Buy |
+2,400
| New | +$310K | ﹤0.01% | 763 |
|
Marshall Wace's ATHN Position: Q1 2019 in Review
Marshall Wace sold out of Athenahealth, Inc. (ATHN) in Q1 2019, closing a stake of 182,403 shares — an estimated $24.1M sold.
Marshall Wace first reported a position in ATHN in Q2 2014 and held it in 10 quarters. The position peaked at $24.1M in Q4 2018. 0 funds tracked by Wall St. Rank hold ATHN as of Q1 2019.
- Marshall Wace reported no remaining Athenahealth, Inc. position as of Q1 2019 after selling out during the quarter.
- Marshall Wace sold 182,403 Athenahealth, Inc. shares in Q1 2019, an estimated $24.1M.
- Marshall Wace first reported a position in Athenahealth, Inc. in Q2 2014 and held it in 10 quarters.
- Marshall Wace's Athenahealth, Inc. position peaked at $24.1M in Q4 2018.
- 0 funds tracked by Wall St. Rank held Athenahealth, Inc. as of Q1 2019.
Based on Marshall Wace's 13F filing for Q1 2019, filed 14 May 2019.